ADVISORY BOARD Clinical Trials in Oncology Advisory Board


CESARE SPADONI PHD MBA, CO-FOUNDER AND CHIEF OPERATING OFFICER OF ONCOHEROES BIOSCIENCES INC.


Cesare is co-founder and Chief Operating Officer of Oncoheroes Biosciences Inc., a Boston- based biotech company focused on pediatric oncology drug development. Cesare has more than 20 years of experience in the drug development field, in both scientific and commercial roles. Previously, he held senior positions at AMRI, Aptuit Laurus, ThalesNano and Auxiliis. Cesare started his career as research scientist in a pharmaceutical company (Eisai, London) and in academia (Institute of Enzymology, Budapest).


Following the death of his first daughter Laura to cancer, Cesare set up aPODD Foundation, a London-based


charity focused on accelerating paediatric oncology drug development. As aPODD’s chairman he is actively involved on a pro-bono basis in drug repurposing projects, advocacy efforts and research collaborations. Cesare holds an MSc in Applied Molecular Biology and a PhD in Neurosciences from UCL, University of London, as well as an MBA from the Central European University, Budapest.


FATIMA SCIPIONE, VICE PRESIDENT OF GLOBAL PATIENT AFFAIRS AT BLUEPRINT MEDICINES


Fatima serves as the Vice President of Global Patient Affairs at Blueprint Medicines, a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. In her role, Fatima leads transformative collaborations with external advocacy


groups, empowering and educating those affected by systemic mastocytosis. She has led the launch of significant initiatives such as GRTY Health’s SM patient platform, MastoConnect, and Colors of SM, in partnership with the advocacy community, and actively chairs the Equity, Diversity, and Inclusion (ED&I) patient committee, which looks to address the needs of marginalized and underrepresented communities. With over two decades of experience in the biopharma sector, Fatima is a dedicated and passionate advocate


for patients. Celebrated by PharmaVoice 100 as one of the most inspiring leaders in patient advocacy, her work focuses on amplifying patient voices and harnessing the collective power of individuals to make a positive impact. Fatima is committed to enhancing patient engagement in the development of transformative medicines, ensuring that the patient perspective is integral to every stage of the process. She inspires her colleagues to foster a culture of purpose-driven advocacy, ensuring that patient welfare


remains at the forefront of their mission. Beyond her professional role, Fatima is deeply involved in civic activities, continually dedicating herself to enhancing patient welfare and advocacy on a broader scale.


FRANK RICHARD, MD, MBA, VP MEDICAL AT HEIDELBERG PHARMA AG


Frank Richard, MD, MBA is a seasoned medical doctor and has over 20 years of development experience in R&D. In his current role as VP Medical at Heidelberg Pharma AG, Germany, he is providing medical strategy and oversight for the preparation and conduct of phase I-III clinical studies using antibody-drug conjugates (ADCs). Additionally, he supports modelling &simulation activities to understand how to effectively use preclinical data from in vivo studies, mechanistic modeling, and


bioanalysis to improve dose prediction and determine the optimal dose when introducing an ADC into clinical trials in various cancer indications. Frank has been working in the past in Immune-Oncology, Immunology& Respiratory, Rare Hematology Diseases and Iron Metabolism across big pharma and biotech. Frank holds a MD from Charité Medical University, Berlin, an MBA from University of Applied Sciences, Neu- Ulm, and is a board-certified Clinical Pharmacologist. Additionally, he exerts an unique expertise and interest in Bayesian Statistics and machine learning in Pharma


and Biotech. 42 | Clinical Trials in Oncology


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44